Embolic compositions and methods
US-2024342338-A1 · Oct 17, 2024 · US
US12138362B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12138362-B2 |
| Application number | US-202318510358-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 15, 2023 |
| Priority date | Mar 26, 2015 |
| Publication date | Nov 12, 2024 |
| Grant date | Nov 12, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Embolic particles are described. The particles are reaction products of a prepolymer solution including at least one polyether macromer and an appropriate monomer.
Opening claim text (preview).
We claim: 1. An embolic, including: embolic particles having an organic polymer backbone including a reaction product of a prepolymer solution including: a poly(ethylene glycol) diacrylamide macromer, a poly(ethylene glycol) diacrylate macromer, a poly(ethylene glycol) dimethacrylate macromer, a poly(ethylene glycol) dimethacrylamide macromer, or a combination thereof; and aminopropyl methacrylamide, wherein the embolic particles have a diameter between about 50 μm and about 1,500 μm. 2. The embolic of claim 1 , wherein the diameter is between about 400 μm and about 1,500 μm. 3. The embolic of claim 1 , wherein the aminopropyl methacrylamide is N-(3-aminopropyl methacrylamide). 4. The embolic of claim 1 , further including at least one monomer that includes ionic groups. 5. The embolic of claim 3 , wherein the monomer including ionic groups is 3-sulfopropyl acrylate or a salt thereof. 6. The embolic of claim 1 , wherein the prepolymer solution further includes a crosslinker having a structure: wherein each n is independently 1-20; wherein d, e, and f are each independently 1-20; or 7. The embolic of claim 5 , wherein the crosslinker is biodegradable. 8. The embolic of claim 1 , wherein the embolic particles further include a visualization agent having a structure: 9. A method of treatment, the method comprising: delivering embolic particles to a treatment site, wherein the embolic particles have an organic polymer backbone and are formed from a reaction product of a prepolymer solution including: a poly(ethylene glycol) diacrylamide macromer, a poly(ethylene glycol) diacrylate macromer, a poly(ethylene glycol) dimethacrylate macromer, a poly(ethylene glycol) dimethacrylamide macromer, or a combination thereof; and aminopropyl methacrylamide, wherein the embolic particles have a diameter between about 50 μm and about 1,500 μm. 10. The method of claim 9 , wherein the aminopropyl methacrylamide is N-(3-aminopropyl methacrylamide). 11. The method of claim 9 wherein the embolic particles are delivered through a delivery device. 12. The method of claim 10 , wherein the delivery device is jailed by a flow diverting stent. 13. The method of claim 12 , wherein the flow diverting stent includes a material having a pore size that is less than the diameter. 14. The method of claim 9 , wherein the delivering includes flushing the catheter with a non-solvent. 15. The method of claim 14 , wherein the non-solvent is a mineral oil, hexane, or water. 16. The method of claim 9 , wherein the delivery device is a catheter or a microcatheter. 17. The method of claim 9 , further including at least one monomer that includes ionic groups. 18. The method of claim 9 , wherein the prepolymer solution further includes a crosslinker having a structure: wherein each n is independently 1-20; wherein d, e, f, and g are each independently 1-20; or 19. The method of claim 18 , wherein the crosslinker is biodegradable. 20. The method of claim 9 , wherein the embolic particles further include a visualization agent having a structure:
for embolization or occlusion, e.g. vaso-occlusive compositions or devices · CPC title
Use of materials characterised by their function or physical properties · CPC title
Monomers containing two or more (meth)acrylamide groups, e.g. N,N'-methylenebisacrylamide · CPC title
obtained by reactions only involving carbon-to-carbon unsaturated bonds {(A61L24/043, A61L24/046 take precedence)} · CPC title
Homopolymers or copolymers of acrylamide or methacrylamide · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.